Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma Inc (NQ: ALBO )

22.71 +0.54 (+2.46%)
Streaming Delayed Price Updated: 10:23 AM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,240
Open 22.25
Bid (Size) 22.53 (2)
Ask (Size) 22.72 (2)
Prev. Close 22.17
Today's Range 22.15 - 23.17
52wk Range 20.30 - 37.86
Shares Outstanding 19,576,319
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
81 Biggest Movers From Yesterday
Gainers Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results. 
Via Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Okyo Pharma Ltd. ADR (NASDAQ: OKYO) gained 30% to $5.20 as the company priced its IPO at $4 per ADS. 
Via Benzinga

Performance

YTD
-6.56%
-6.56%
1 Month
-36.14%
-36.14%
3 Month
-32.34%
-32.34%
6 Month
-9.07%
-9.07%
1 Year
-24.78%
-24.78%

More News

Read More
Mid-Morning Market Update: Markets Open Higher; Walmart Earnings Miss Estimates
Via Benzinga
Albireo Pharma: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For May 16, 2022
Via Benzinga
Albireo Pharma's Earnings Outlook
Via Benzinga
Albireo Pharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Recap: Albireo Pharma Q4 Earnings
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
80 Biggest Movers From Yesterday
Via Benzinga
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Via Benzinga
Albireo Pharma, inc (ALBO) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Albireo Pharma Sells Bylvay-Associated PRV For $105M
Via Benzinga
Exposures Product Safety
Looking into Albireo Pharma's Return on Capital Employed
Via Benzinga
Albireo Pharma, inc (ALBO) Q2 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Via Benzinga
Exposures Product Safety
Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Via Benzinga
Exposures Product Safety
Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease
Via Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
Via Benzinga
Albireo's Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.